- Shares of Gossamer Bio have rebounded some 75% off their lows set in mid-July and have pivoted away from its failed asthma asset GB001.
- Merck’s $11 billion overture for Acceleron and its PAH candidate (sotatercept), in addition to positive commentary from Piper have also boosted Gossamer’s stock price.
- The relative lack of hard efficacy data for Gossamer’s current clinical compounds will end with two Phase 2 readouts in 1H22, merited a deeper dive into this busted IPO.
- A full analysis follows in the paragraphs below.
For further details see:
Gossamer Bio: Circling Back After A Rebound Off Lows